Abbott Laboratories $ABT Stock Sold by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund lessened its position in Abbott Laboratories (NYSE:ABT – Free Report) by 6.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 188,391 shares of the healthcare product maker’s stock after selling 13,427 shares during the period. Illinois Municipal Retirement Fund’s holdings in Abbott Laboratories were worth $18,619,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Elwood & Goetz Wealth Advisory Group LLC raised its stake in shares of Abbott Laboratories by 3.1% during the third quarter. Elwood & Goetz Wealth Advisory Group LLC now owns 3,216 shares of the healthcare product maker’s stock valued at $318,000 after acquiring an additional 97 shares during the last quarter. Parkway Wealth Management Group LLC grew its stake in shares of Abbott Laboratories by 3.2% in the third quarter. Parkway Wealth Management Group LLC now owns 3,208 shares of the healthcare product maker’s stock worth $317,000 after purchasing an additional 98 shares during the last quarter. Signature Equity Partners LLC increased its holdings in Abbott Laboratories by 7.9% during the 3rd quarter. Signature Equity Partners LLC now owns 1,363 shares of the healthcare product maker’s stock valued at $135,000 after purchasing an additional 100 shares during the period. St. Johns Investment Management Company LLC increased its holdings in Abbott Laboratories by 1.0% during the 2nd quarter. St. Johns Investment Management Company LLC now owns 9,859 shares of the healthcare product maker’s stock valued at $895,000 after purchasing an additional 101 shares during the period. Finally, AA Financial Advisors LLC increased its holdings in Abbott Laboratories by 1.7% during the 3rd quarter. AA Financial Advisors LLC now owns 6,186 shares of the healthcare product maker’s stock valued at $611,000 after purchasing an additional 101 shares during the period. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 1.0%

Shares of ABT opened at $109.38 on Thursday. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $132.02. The company has a current ratio of 1.45, a quick ratio of 1.00 and a debt-to-equity ratio of 0.57. The firm’s 50-day moving average price is $104.00 and its 200-day moving average price is $101.74. The firm has a market capitalization of $189.43 billion, a price-to-earnings ratio of 40.81, a PEG ratio of 1.94 and a beta of 0.54.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.42. Abbott Laboratories had a net margin of 9.75% and a return on equity of 18.04%. The company had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. During the same period in the prior year, the firm earned $1.30 earnings per share. Abbott Laboratories’s revenue was up 14.5% on a year-over-year basis. Sell-side analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is 94.03%.

Insider Activity

In other news, EVP Mary Moreland sold 3,500 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total value of $406,000.00. Following the completion of the transaction, the executive vice president owned 100,791 shares of the company’s stock, valued at approximately $11,691,756. This represents a 3.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Argus cut Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, October 27th. Wells Fargo & Company boosted their target price on Abbott Laboratories from $112.00 to $119.00 and gave the company an “overweight” rating in a research note on Thursday, October 22nd. Royal Bank Of Canada reduced their target price on Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Thursday, October 22nd. Robert W. Baird upped their target price on Abbott Laboratories from $121.00 to $123.00 and gave the company an “outperform” rating in a report on Thursday, October 22nd. Finally, BTIG Research dropped their price target on Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating for the company in a research note on Thursday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $118.32.

View Our Latest Analysis on ABT

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

See Also

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.